Viralytics (ASX: VLA, OTCQX:VRACY) has achieved the target enrolment for the Phase 2 melanoma trial for its CAVATAK anti-cancer drug for the treatment of late stage melanoma.
The 54th patient has been injected with the drug while interim results show that 14 of the 40 evaluable patients reaching the six month immune related Progression Free Survival target.
In addition, there is promising one year survival data with 12 of first 20 patients still alive at that stage.
The Phase 2 trial is a single arm study being conducted at 11 US cancer clinics to investigate the safety and efficacy of intratumoral CAVATAK in patients with late stage malignant melanoma.
Proactive Investors Australia is the market leader in producing news, articles and research reports on ASX “Small and Mid-cap” stocks with distribution in Australia, UK, North America and Hong Kong / China.